Treatment of childhood post-irradiation sarcoma of bone in cancer survivors

✍ Scribed by Cefalo, Graziella; Ferrari, Andrea; Tesoro-Tess, John D.; Gianni, Maria C.; Fossati-Bellani, Franca; Lombardi, Fabrizio; Massimino, Maura

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 176 KB
• Volume: 29
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199712)29:6<568::aid-mpo9>3.0.co;2-i

✦ Synopsis

Patients and Methods. This is a retrospective review of five children with post-irradiation bone sarcoma (PIS). Age at PIS onset ranged between 10 and 17 years (median 11). They were treated with a chemotherapy regimen, similar to that in use for primary osteogenic sarcoma, consisting of vincristine and high-dose methotrexate alternated with cisplatinum and ifosfamide, given for 12 months.

Results. In all children chemotherapy induced a complete clinical remission. Four of them were alive in continuous complete remission at 1, 2, 4, and 12 years from the diagnosis of bone sarcoma. One girl recurred 3 years from PIS diagnosis and was salvaged by repeating the same chemotherapy program: she remained alive in second complete remission 8 years from relapse.

Conclusions. In spite of an intensive treatment previously given for the primary tumor, this drug schedule proved to be feasible and short-term side effects were manageable. Chemotherapy alone, using an intensive regimen effective for primary osteogenic sarcoma, may be an adequate therapy for childhood postirradiation sarcoma. Med.